

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jul 2026

### Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled Trial

#### Protocol summary

##### Study aim

By Comparing the Effectiveness of Topical Oxybutynin Gel 10% and Aluminum Chloride 20% in Patients with Hyperhidrosis, It is Possible to Choose a More Effective Treatment method to Treat this Disease and Help Reduce the Complications Caused by This Disease.

##### Design

This Study is a Phase 4 Single-Blind Study That Includes 30 Patients. Patients are Individuals with Palmar and Axillary Hyperhidrosis Who Meet the Conditions for Entering the Study

##### Settings and conduct

A Double-Blind Clinical Trial With 30 Cases of Primary Hyperhidrosis Referred to Afzalipour Hospital, Kerman. Each Side of the Body, Were Randomly Treated with Drug a or b, Once a Day for two Months. At the Beginning and End of the Study, The Iodine-Starch Test, The Hyperhidrosis Severity Scale, Quality of Life Index, Severity of Complications and Rate of Patient Satisfaction Are Evaluated Through a Questionnaire. The Doctor Examining the Effectiveness of the Treatment are Not Aware of the Type of Treatment Performed on Both Sides of The Body

##### Participants/Inclusion and exclusion criteria

Inclusion Criteria: Patients with Primary Hyperhidrosis of the Palms and Axilla with Intensity 3 and Above and Aged 60-18 Exclusion Criteria: Iontophoresis, Botulinum Toxin Injection, Topical Antiperspirants, Sympathectomy In the Last 6 Months, Pregnant and Lactating Women, Secondary Hyperhidrosis, Sjogren or Sikka Syndrome, Allergy to Aluminum Salts

##### Intervention groups

This is a Split Study. One Side of The Patient's Body Is Treated with the First Drug and the Other Side is Treated with the Second Drug. One Container of Drug Contains the Topical Gel Contains 10% Oxybutynin and the Other One Contains 20% Aluminum Chloride

#### Main outcome variables

Severity of the disease, HDSS and DLQI Rating, Site of Involvement and Complications of the Disease

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20221110056463N2**

Registration date: **2023-06-13, 1402/03/23**

Registration timing: **retrospective**

Last update: **2023-06-13, 1402/03/23**

Update count: **0**

##### Registration date

2023-06-13, 1402/03/23

##### Registrant information

##### Name

Najmeh Ahramianpour

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 917 370 3643

##### Email address

n.ahramianpour@kmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2022-11-21, 1401/08/30

##### Expected recruitment end date

2022-12-21, 1401/09/30

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled Trial

**Public title**

Comparison of the Effectiveness of 10% Oxybutynin Topical Gel and 20% Aluminum Chloride in Patients with Primary Hyperhidrosis: a Randomized Double-Blind Controlled Trial

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Primary Excessive Sweating with a Score of 3 or Higher on the Hyperhidrosis Disease Severity Scale (HDSS), at Least in the last 6 Months No Treatment during 6 Months before Entering the Study with Iontophoresis, Botulinum Toxin Injection no Performance of Sympathectomy

**Exclusion criteria:**

Pregnant and Lactating Women People who have Secondary Excessive Sweating due to an External Factor People with Active Skin Disease such as: Psoriasis, Eczema, Seborrhea and Skin Infection, Glaucoma, Urinary Retention, Myasthenia Gravis, Sjögren's Syndrome or Sicca Syndrome History of Allergy to Aluminum Salts

**Age**

From **18 years** old to **60 years** old

**Gender**

Both

**Phase**

4

**Groups that have been masked**

- Outcome assessor

**Sample size**

Target sample size: **30**

**Randomization (investigator's opinion)**

N/A

**Randomization description****Blinding (investigator's opinion)**

Single blinded

**Blinding description**

The Study is Single-Blind. In this Way: The Person Evaluating the Outcome Does Not Have any Information About the Content of the Drug Used in Each Side and only Checks the Effectiveness of Each Side and Compares it With the Other Side.

**Placebo**

Not used

**Assignment**

Factorial

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Kerman University of Medical Sciences

**Street address**

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7171791661

**Approval date**

2022-11-17, 1401/08/26

**Ethics committee reference number**

IR.KMU.AH.REC.1400.234

**Health conditions studied****1****Description of health condition studied**

Primary Hyperhidrosis

**ICD-10 code**

R61

**ICD-10 code description**

Generalized hyperhidrosis

**Primary outcomes****1****Description**

Severity of Hyperhidrosis

**Timepoint**

At the Beginning, Day 30 and 60

**Method of measurement**

Hyperhidrosis Disease Severity Scale Questionnaire

**2****Description**

Dermatology Quality of Life

**Timepoint**

At the Beginning, Day 30 and 60

**Method of measurement**

DLQI Questionnaire

**3****Description**

Severity of Complications

**Timepoint**

At the Beginning of the Study and Day 30 and 60

### Method of measurement

A self-Made Questionnaire with a Score of 0-2 to Check the Severity of the Complication

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention Group: The First Group: A Patient with Hyperhidrosis of the Palm or Axilla, Is Treated with a Topical Gel Containing 10% Oxybutynin on One Side of the Body. It is Explained to the Patient That at Night, 1 cm of the Gel Should Be Applied on the Clean and Dry Skin of the Same Side and It Should Not be Washed For 4 Hours after Use. Use and In the Next 30 Days Reduce It to Once Every Other Night

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: The second group: a patient with hyperhidrosis of the palm or axilla, is treated with a topical gel containing 20% aluminum chloride on the other side of the body. It is explained to the patient that at night, 1 cm of the gel should be applied on the clean and dry skin of the same side and it should not be washed for 4 hours after use. use and in the next 30 days reduce it to once every other night

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Afzalipour Hospital, Kerman

##### Full name of responsible person

Najmeh Ahramyanpour

##### Street address

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman,Iran

##### City

Kerman

##### Province

Kerman

##### Postal code

7171791661

##### Phone

+98 917 370 3643

##### Email

n.ahramianpour@kmu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Kerman University of Medical Sciences

##### Full name of responsible person

Najmeh Ahramyanpour

##### Street address

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman, Iran

##### City

Kerman

##### Province

Kerman

##### Postal code

7171791661

##### Phone

+98 34 3132 8237

##### Email

n.ahramianpour@kmu.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Kerman University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Kerman University of Medical Sciences

##### Full name of responsible person

Najmeh Ahramyanpour

##### Position

Assistant Professor

##### Latest degree

Specialist

##### Other areas of specialty/work

Dermatology

##### Street address

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman,Iran

##### City

Kerman

##### Province

Kerman

##### Postal code

7171791661

**Phone**

0098341328237

**Email**

najmeh.pour@gmail.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Najmeh Ahramianpour

**Position**

Assistant professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7171791661

**Phone**

+98 917 370 3643

**Fax**

**Email**

n.ahramian@kmu.ac.ir

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Najmeh Ahramianpour

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dermatology

**Street address**

Imam Khomeini Highway, Next to Shahid Bahonar University, Afzalipour Hospital, Kerman, Iran

**City**

Kerman

**Province**

Kerman

**Postal code**

7171791661

**Phone**

+98 917 370 3643

**Fax**

**Email**

n.ahramian@kmu.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available